Lilly and Laekna team up on novel obesity drugs

21 November 2024

Eli Lilly (NYSE: LLY) is not resting on its laurels when it comes to the fast-growing field of obesity treatments, an area in which it is already a leader.

The American firm has announced a clinical partnership with Hong Kong’s Laekna Therapeutics (HKEX: 2105) to advance LAE102, an antibody targeting the ActRIIA receptor.

The collaboration will focus on Phase I development of the molecule, including in obesity, with Lilly funding the work and providing resources to accelerate R&D. Laekna retains global rights to the candidate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK